SHARE NOW
Scribe Therapeutics expands collaboration with Sanofi to propel a new influx of in vivo genetic medicines for sickle cell and other genomic diseases. The in vivo collaboration leverages Scribe’s CRISPR XE technologies and Sanofi’s capabilities in non-viral delivery to combat sickle cell disease.
Scribe Therapeutics Inc., a genetic medicines company, announced the expansion of its collaboration with Sanofi. Sanofi is to receive an exclusive license to use Scribe’s CRISPR X-Editing (XE) genome editing technologies, under the agreement, for the development of in vivo therapies, including sickle cell disease.
“We are continually impressed by the expertise, rigor, and urgency that Sanofi has brought to our existing ex vivo collaboration, as well as their rapid advancements and innovation in non-viral delivery technologies. Now, we are thrilled to expand our work together into new areas of high unmet need,” said Benjamin Oakes, Ph.D., co-founder and CEO of Scribe.
The Companies’ existing collaboration focused on cancer treatment using ex vivo editing of natural killer cell therapies. Under the terms of the agreement, Scribe will receive an upfront payment of $40 million and is eligible to potentially receive more than $1.2 billion based on the successful completion of certain development and sales targets.
The in vivo collaboration leverages Scribe’s CRISPR XE technologies and Sanofi’s capabilities in non-viral delivery to combat sickle cell disease. Scribe’s CRISPR by Design™ powers the only platform that uses holistic engineering to transform bacterial immune systems genome editing technologies suitable for advanced therapies.
“This in vivo collaboration further demonstrates the versatility of Scribe’s design-based approaches to CRISPR, which enable greater activity, specificity, and deliverability, ultimately accelerating the development of life-changing therapeutics,” added Oakes.
How are you enjoying this news article? Let us know your thoughts, here >>
Scribe’s tools for in vivo genome editing uses an innovative approach with the potential to minimize complication associated with investigational ex vivo autologous treatments such as conditioning regimen toxicities.
“We’re encouraged by what we’ve accomplished to date with Scribe in creating ex vivo NK cell therapies and now look forward to accelerating our ability to effectively leverage genome editing in vivo through Sanofi’s innovative research work in targeted lipid nanoparticles (LNPs), for in vivo therapies with the potential to dramatically improve treatment outcomes and ultimately to change patients’ lives,” commented Christian Mueller, Global Head of Genomic Medicine Unit at Sanofi.
Source: Scribe Press Release
While we have you…
We are continuously working to better optimize our content for you, our audience. Let us know how we’re doing by ticking the box below, or send us your feedback directly to team@phacilitate.com.
